Triggering Fcα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy

B Stockmeyer, M Dechant, M van Egmond… - The Journal of …, 2000 - journals.aai.org
CD20 Abs induce clinical responses in lymphoma patients, but there are considerable
differences between individual patients. In 51 Cr release assays with whole blood as effector …

[HTML][HTML] Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

V Ramakrishna, K Sundarapandiyan, B Zhao… - … for immunotherapy of …, 2015 - Springer
Background Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with
immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy …

Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy

LA Vitale, LJ Thomas, LZ He, T O'Neill, J Widger… - Cancer Immunology …, 2019 - Springer
Limitations of immunotherapy include poorly functioning events early in the immune
response cycle, such as efficient antigen presentation and T cell priming. CD40 signaling in …

Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood

YM Deo, K Sundarapandiyan, T Keler… - The Journal of …, 1998 - journals.aai.org
Abstract The FcR for IgA (FcαRI, CD89) is primarily expressed on cytotoxic immune effector
cells. By chemically cross-linking F (ab′) fragments of the FcR for IgA (FcαRI)-specific mAb …

Development of a novel antibody–drug conjugate for the potential treatment of ovarian, lung, and renal cell carcinoma expressing TIM-1

LJ Thomas, L Vitale, T O'Neill, RY Dolnick… - Molecular Cancer …, 2016 - AACR
T-cell immunoglobulin and mucin domain 1 (TIM-1) is a type I transmembrane protein that
was originally described as kidney injury molecule 1 (KIM-1) due to its elevated expression …

Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice

T Keler, PM Guyre, LA Vitale… - The Journal of …, 2000 - journals.aai.org
Previous studies have documented that targeting foreign Ags to IgG FcγR leads to enhanced
Ag-specific responses in vitro and in vivo. However, the ability to overcome immunologic …

Differential effect of cytokine treatment on Fcα receptor I-and Fcγ receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages

T Keler, PK Wallace, LA Vitale… - The Journal of …, 2000 - journals.aai.org
Macrophages represent an important effector cell for Ab-mediated tumor therapy. Previous
studies have documented that cytokines can influence Fc receptor (FcR) expression and …

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells

K Sundarapandiyan, T Keler, D Behnke… - Journal of …, 2001 - Elsevier
CD30 is a molecule that is overexpressed on the surface of Hodgkin's lymphoma cells.
Therefore, CD30 represents a potential candidate for immunotherapy. In this study, we …

Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.

J Goldstein, RF Graziano… - … (Baltimore, Md.: 1950 …, 1997 - journals.aai.org
A bispecific fusion protein (H22-EGF) that binds simultaneously to the epidermal growth
factor receptor (EGF-R) and to the high affinity receptor for the Fc portion of human IgG, Fc …

Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells

C Somasundaram, K Sundarapandiyan… - Human …, 1999 - content.iospress.com
Abstract A trispecific F (ab′) 3 antibody conjugate (TAC) with specificities for the Fcγ
receptor I (FcγRI/CD64), the epidermal growth factor receptor (EGFR) and the HER2/neu …